For the year ending 2025-12-31, AUPH had -$3,220K decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Net income (loss) | 287,202 |
| Deferred income tax benefit | -176,194 |
| Amortization and depreciation | 19,449 |
| Share-based compensation | 14,678 |
| Foreign exchange loss (gain) on revaluation of monoplant finance lease liability | -9,685 |
| Net amortization of premiums and discounts on investments | 10,179 |
| Non-cash write-down of inventory | 0 |
| Other, net | 200 |
| Accounts receivable, net | 4,910 |
| Inventory | 6,462 |
| Prepaid expenses and other current assets | -5,522 |
| Other noncurrent operating assets | -730 |
| Accounts payable | -1,874 |
| Accrued expenses and other liabilities | -4,655 |
| Deferred revenue | 3,668 |
| Operating lease liabilities | -802 |
| Cash flows from operating activities | 135,658 |
| Proceeds from the sale and maturities of investments | 494,134 |
| Purchases of investments | 526,650 |
| Upfront lease payments | 0 |
| Purchases of property, equipment and intangible assets | 252 |
| Cash flows from investing activities | -32,768 |
| Repurchase of common shares | 98,156 |
| Principal portion of finance lease payments | 13,136 |
| Proceeds from issuance of common shares from exercise of stock options and vesting of rsus and performance awards | 14,190 |
| Proceeds from issuance of common shares under espp | 756 |
| Taxes paid related to net settlement of exercises of stock options and vesting of rsus and performance awards | 9,764 |
| Cash flows from financing activities | -106,110 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -3,220 |
| Cash, cash equivalents and restricted cash, beginning of the period | 83,433 |
| Cash, cash equivalents and restricted cash, end of the period | 80,213 |
Aurinia Pharmaceuticals Inc. (AUPH)
Aurinia Pharmaceuticals Inc. (AUPH)